A retrospective study to evaluate survival outcome of patients with EGFR-mutant non-small-cell lung cancer who have progressed on previous EGFR TKI therapy in real world settings
Latest Information Update: 28 Jul 2020
At a glance
- Drugs Osimertinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 28 Jul 2020 New trial record
- 12 Jul 2020 Results published in the Targeted Oncology